ArticleBlood2016
How I treat hepatitis C virus infection in patients with hematologic malignancies.
Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.International journal of cancer · 2018Trial
- Review
- Review
- Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series.Pathogens (Basel, Switzerland) · 2022Article
- Management of hepatitis B and C in special population.World journal of gastroenterology · 2021Review
- Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis.The oncologist · 2020Article
- Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy.Journal for immunotherapy of cancer · 2020Review
- Liver disease during and after hematopoietic stem cell transplantation in adults: a single-center Egyptian experience.Journal of the Egyptian National Cancer Institute · 2020Article
- Effect of Hepatitis B and C Infection on Recruitment for Cancer Clinical Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.Hepatology (Baltimore, Md.) · 2018Observational
- The oncologic burden of hepatitis C virus infection: A clinical perspective.CA: a cancer journal for clinicians · 2017Review
- Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience.Arthritis research & therapy · 2017Article
- Late effects of blood and marrow transplantation.Haematologica · 2017Review
- Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer.Alimentary pharmacology & therapeutics · 2016Observational
- Concurrent Systemic Chemoimmunotherapy and Sofosbuvir-Based Antiviral Treatment in a Hepatitis C Virus-Infected Patient With Diffuse Large B-Cell Lymphoma.Open forum infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-of-care treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCV-infected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An up-to-date treatment algorithm is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.